Search research articles
Contact Us
Filters
Showing results (351-360 of 574) with videos related to
Page
of 58
Sort By:
Brain Research
|
June 27, 2008
Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo
Tianhong Pan, Wen Zhu, Hongru Zhao, et al.
Neuroimage
|
April 21, 2009
Safety of MRI in patients with implanted deep brain stimulation devices
Michele Tagliati, Joseph Jankovic, Fernando Pagan, et al.
The Journal of Comparative Neurology
|
December 2, 2005
Nurr1 in Parkinson's disease and related disorders
Yaping Chu, Weidong Le, Katie Kompoliti, et al.
Experimental Neurology
|
July 24, 2010
Nonlinear temporal organization of neuronal discharge in the basal ganglia of Parkinson's disease patients
Jongil Lim, Manjit K Sanghera, Olivier Darbin, et al.
Molecular Immunology
|
May 2, 2006
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A
Behzod Z Dolimbek, K Roger Aoki, Lance E Steward, et al.
Current Neuropharmacology
|
July 2, 2013
Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Susanne A Schneider, Petr Dusek, John Hardy, et al.
Molecular Immunology
|
August 5, 2008
Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment
M Zouhair Atassi, Behzod Z Dolimbek, Joseph Jankovic, et al.
Archives of Neurology
|
March 14, 2007
A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations
Hao Deng, Wei-Dong Le, Christine B Hunter, et al.
Current Medical Research and Opinion
|
August 13, 2021
Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects
Dimos D Mitsikostas, Andrzej Dekundy, Angelika Hanschmann, et al.
Journal of the Neurological Sciences
|
September 5, 2014
IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated
Virgilio Gerald H Evidente, Daniel Truong, Joseph Jankovic, et al.
Page
of 58
Search research articles
Search
Showing results (351-360 of 574) with videos related to
Sort By:
Page
of 58
Brain Research
|
June 27, 2008
Nurr1 deficiency predisposes to lactacystin-induced dopaminergic neuron injury in vitro and in vivo
Tianhong Pan, Wen Zhu, Hongru Zhao, et al.
Neuroimage
|
April 21, 2009
Safety of MRI in patients with implanted deep brain stimulation devices
Michele Tagliati, Joseph Jankovic, Fernando Pagan, et al.
The Journal of Comparative Neurology
|
December 2, 2005
Nurr1 in Parkinson's disease and related disorders
Yaping Chu, Weidong Le, Katie Kompoliti, et al.
Experimental Neurology
|
July 24, 2010
Nonlinear temporal organization of neuronal discharge in the basal ganglia of Parkinson's disease patients
Jongil Lim, Manjit K Sanghera, Olivier Darbin, et al.
Molecular Immunology
|
May 2, 2006
Mapping of the regions on the heavy chain of botulinum neurotoxin A (BoNT/A) recognized by antibodies of cervical dystonia patients with immunoresistance to BoNT/A
Behzod Z Dolimbek, K Roger Aoki, Lance E Steward, et al.
Current Neuropharmacology
|
July 2, 2013
Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Susanne A Schneider, Petr Dusek, John Hardy, et al.
Molecular Immunology
|
August 5, 2008
Molecular recognition of botulinum neurotoxin B heavy chain by human antibodies from cervical dystonia patients that develop immunoresistance to toxin treatment
M Zouhair Atassi, Behzod Z Dolimbek, Joseph Jankovic, et al.
Archives of Neurology
|
March 14, 2007
A family with Parkinson disease, essential tremor, bell palsy, and parkin mutations
Hao Deng, Wei-Dong Le, Christine B Hunter, et al.
Current Medical Research and Opinion
|
August 13, 2021
Duration and onset of effect of incobotulinumtoxinA for the treatment of blepharospasm in botulinum toxin-naïve subjects
Dimos D Mitsikostas, Andrzej Dekundy, Angelika Hanschmann, et al.
Journal of the Neurological Sciences
|
September 5, 2014
IncobotulinumtoxinA (Xeomin®) injected for blepharospasm or cervical dystonia according to patient needs is well tolerated
Virgilio Gerald H Evidente, Daniel Truong, Joseph Jankovic, et al.
Page
of 58